Switching to raltegravir (RAL) from stavudine (d4T) improved limb fat content in HIV-1 controlled patients with lipoatrophy (LA). SWIMIVIR. A prospective pilot study

被引：0

|

作者：

Domingo, P.

Estrada, V. ^{[1
]}

Mateo, G.

Rodrigo, M. ^{[1
]}

Santos, I. ^{[2
]}

Moreno, M. E.

Fumero, E.

机构：

[1] Hosp Univ San Carlos, Madrid, Spain

[2] Hosp La Princesa, Madrid, Spain

来源：

ANTIVIRAL THERAPY | 2010年 / 15卷 / 08期

关键词：

D O I：

暂无

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

引用

收藏

页码：A33 / A34

页数：2

相关论文

共 2 条

[1] Switching to raltegravir (RAL) from stavudine (d4T) improved limb fat content in HIV-1 controlled patients with lipoatrophy (LA). SWIMIVIR. A prospective pilot study
Domingo, P.
Estrada, V.
Mateo, G.
Rodrigo, M.
Santos, I.
Moreno, M. E.
Fumero, E.
ANTIVIRAL THERAPY, 2010, 15 : A33 - A34
[2] Improvement in lipoatrophy and lipid abnormalities following switch from stavudine (d4T) to tenofovir DF (TDF) in combination with lamivudine (3TC) and efavirenz (EFV) in HIV-infected patients: a 48-week follow-up from study 903E
Zhong, L
Cotton, G
Enejosa, J
Cheng, AK
ANTIVIRAL THERAPY, 2005, 10 (08) : L40 - L40